Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA

References

• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar;18(3):268–281. ​
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Active bacterial core surveillance report, emerging infections program network, methicillin resistant Staphylococcus aureus, 2014. [cited 2016 Sep 1]. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/mrsa14.pdf Updated March 1, 2016.
   Google Scholar
• Kock R, Becker K, Cookson B, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15:19688.
   PubMedGoogle Scholar
• Gould IM. Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents. 2006;28:379–384.
   PubMed Web of Science ®Google Scholar
• Gould IM. Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA). Int J Antimicrob Agents. 2013 Jun;42(Suppl):S17–21.
   PubMed Web of Science ®Google Scholar
• VanEperen AS, Segreti J. Empirical therapy in methicillin-resistant Staphylococcus aureus infections: an up-to-date approach. J Infect Chemother. 2016 Jun;22(6):351–359.
   PubMed Web of Science ®Google Scholar
• Holubar M, Meng L, Deresinski S. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: new Therapeutic Approaches. Infect Dis Clin North Am. 2016 Jun;30(2):491–507.
   PubMed Web of Science ®Google Scholar
• Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet. 2008;47(1):21–33.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Clin Pharmacokinet. 2008;47(1):21–33.
   PubMed Web of Science ®Google Scholar
• Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2001 Mar;45(3):825–836.
   PubMed Web of Science ®Google Scholar
• Jones RN, Deshpande LM, Mutnick AH, et al. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother. 2002 Dec;50(6):915–932.
   PubMed Web of Science ®Google Scholar
• Von Eiff C, Friedrich AW, Becker K, et al. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob Agents Chemother. 2005 Oct;49(10):4372–4374.
   PubMed Web of Science ®Google Scholar
• Pillar CM, Aranza MK, Shah D, et al. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother. 2008 Mar;61(3):595–602.
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis. 2008 May;61(1):86–95.
   PubMed Web of Science ®Google Scholar
• Amsler KM, Davies TA, Shang W, et al. In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2008 Sep;52(9):3418–3423.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu Y, Sun H, et al. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China. Diagn Microbiol Infect Dis. 2008 Oct;62(2):226–229.
   PubMed Web of Science ®Google Scholar
• Silva N, Radhouani H, Gonçalves A, et al. In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals. J Antimicrob Chemother. 2010 Apr;65(4):801–803.
   PubMed Web of Science ®Google Scholar
• Walkty A, Adam HJ, Laverdière M, et al. Canadian Antimicrobial Resistance Alliance (CARA). In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 2011 Mar;69(3):348–355.
   PubMed Web of Science ®Google Scholar
• Bogdanovich T, Ednie LM, Shapiro S, et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 2005 Oct;49(10):4210–4219.
   PubMed Web of Science ®Google Scholar
• Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis. 2007 Jul;58(3):363–365.
   PubMed Web of Science ®Google Scholar
• Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Aug;52(8):2974–2976.
   PubMed Web of Science ®Google Scholar
• Borbone S, Campanile F, Bongiorno D, et al. In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2010 Mar;65(3):591–594.
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Pawlak J, Johnson LB, et al. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents. 2010 Nov;36(5):478–480.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Flamm RK, Sader HS, et al. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. Int J Antimicrob Agents. 2014 Apr;43(4):323–327.
   PubMed Web of Science ®Google Scholar
• Issa NC, Rouse MS, Piper KE, et al. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn Microbiol Infect Dis. 2004 Jan;48(1):73–75.
   PubMed Web of Science ®Google Scholar
• Cereda RF, Azevedo HD, Girardello R, et al. INVITA-A-CEFTO Brazilian Study Group Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study. Braz J Infect Dis. 2011 Jul-Aug;15(4):339–348.
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother. 2008 Oct;52(10):3492–3496.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004 Jul;48(7):2576–2580.
   PubMed Web of Science ®Google Scholar
• An open-label pharmacokinetic study of ceftobiprole in healthy subjects and subjects with end stage renal disease receiving hemodialysis. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Protocol Number: 30982081-CSI-1007. Accessed 2016 Sep 1
   Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun;14(6):498–509.
   PubMed Web of Science ®Google Scholar
• Torres A, Sanchez-Garcia M, Demeyer I, et al. Pharmacokinetics, safety and tolerability of high-dose ceftobiprole medocaril administered as prolonged infusion in intensive-care-unit (ICU) patients [abstract O199]. 25th European Congress of Clinical Microbiology and Infectious Diseases; 25–28 Apr 2015: Copenhagen
   Google Scholar
• Schmitt-Hoffman A, Engelhardt M, Spickermann J, et al. Pharmacokinetics and pharmacodynamics of ceftobiprole in adults who are severely obese [abstract]. Presented at the 26th Annual European Congress of Clinical Microbiology and Infectious Diseases; 9–12 Apr 2016: Amsterdam
   Google Scholar
• Blumer JL, Schmitt-Hoffman A, Engelhardt M, et al. Pharmacokinetics of ceftobiprole in paediatric patients [abstract]. Presented at the 26th Annual European Congress of Clinical Microbiology and Infectious Diseases; 9–12 Apr 2016: Amsterdam
   Google Scholar
• Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother. 2006 Apr;50(4):1376–1383.
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10.
   PubMed Web of Science ®Google Scholar
• Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;1995(22):89–96.
   Web of Science ®Google Scholar
• Mouton JW, Schmitt-Hoffmann A, Shapiro S, et al. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother. 2004 May;48(5):1713–1718.
   PubMed Web of Science ®Google Scholar
• Lodise TP Jr, Pypstra R, Kahn JB, et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother. 2007 Jul;51(7):2378–2387.
   PubMed Web of Science ®Google Scholar
• Kimko H, Murthy B, Xu X, et al. Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2009 Mar;53(3):1228–1230.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011 Oct;50(10):637–664.
   PubMed Web of Science ®Google Scholar
• Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob Agents Chemother. 2008 Jul;52(7):2389–2394.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Nicolau DP, Lodise TP, et al. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother. 2009 Aug;53(8):3294–3301.
   PubMed Web of Science ®Google Scholar
• Kimko H, Xu X, Nandy P, et al. Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2009 Aug;53(8):3371–3374.
   PubMed Web of Science ®Google Scholar
• Barbour A, Schmidt S, Sabarinath SN, et al. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob Agents Chemother. 2009 Jul;53(7):2773–2776.
   PubMed Web of Science ®Google Scholar
• Muller AE, Schmitt-Hoffmann AH, Punt N, et al. Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study. Antimicrob Agents Chemother. 2013;57(5):2047–2053.
   PubMed Web of Science ®Google Scholar
• Muller AE, Punt N, Mouton JW. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. Antimicrob Agents Chemother. 2014 May;58(5):2512–2519.
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008 Jan;52(1):37–44.
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008 Mar 1;46(5):647–655.
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Welte T, File TM Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012 Mar;39(3):240–246.
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014 Jul 1;59(1):51–61.
   PubMed Web of Science ®Google Scholar
• Macdonald A, Dow G. Ceftobiprole: first reported experience in osteomyelitis. Can J Infect Dis Med Microbiol. 2010;213:138–140. Fall.
   PubMed Web of Science ®Google Scholar
• Zevtera ®[package insert]. Basilea Pharmaceutica Ltd., Basel, Switzerland; December 2014. [cited 2016 Sep 1]. Available from: https://www.medicines.org.uk/emc/PIL.29755.latest.pdf.
   Google Scholar
• Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections [news release]. Basel, Switzerland:Basilea Pharmaceutica Ltd. October 12, 2015. [cited 2016 July 27]. Available from: http://www.basilea.com/News-and-Media/Basilea-announces-that-Health-Canada-approved-ZEVTERA-for-the-treatment-of-bacterial-lung-infections/60ac1f4a-5169-0122-7c39-0fa19fc54c51/ ​
   Google Scholar
• Food and drug administration Warning Letter  [news release]. Rockville, MD: Public Health Service, Food and Drug Administration. Warning Letter Sent to Johnson & Johnson Pharmaceutical Research & Development, LLC August 10, 2009. [cited 2016 Aug 26]. Available from: .https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2009/ucm177398.htm ​
   Google Scholar
• Basilea to regain full global rights to ceftobiprole [news release]. Basel, Switzerland. Basilea Pharmaceutica Ltd.  February 19, 2010. [cited 2016 Jul 27]. Available from: http://www.basilea.com/News-and-Media/Basilea-to-regain-full-global-rights-to-ceftobiprole/341/ ​
   Google Scholar